Patients from 22+ countriesPlan your visit →
lutetium-therapy
Treatment Abroad · 31 Aug 2026

PRRT in India for GEP-NET Patients from Africa

If you have a GEP-NET and live in Nigeria, Kenya, or Ethiopia, Lu-177 DOTATATE PRRT is likely unavailable locally. This guide explains the access gap, what treatment in India costs compared to the United States, and how to arrange your care step by step.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 31 Aug 2026
PRRT in India for GEP-NET Patients from Africa

PRRT in India for GEP-NET Patients from Africa

This article is for patients on the DOTATATE track - those with gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. If you have prostate cancer, see our articles on Lu-177 PSMA therapy instead.

If you or someone you care for has a GEP-NET and lives in West or East Africa, one question comes up fast: can I get PRRT here? PRRT - peptide receptor radionuclide therapy - is a targeted radiation treatment that may slow or shrink somatostatin receptor-positive neuroendocrine tumors. The short answer is that most hospitals in sub-Saharan Africa don't have the specialized equipment and training needed to deliver this treatment yet. But PRRT is not out of reach. For many patients in Nigeria, Kenya, and Ethiopia, India has become the most practical place to get this therapy.

This guide explains what PRRT is, why it's not available locally yet, what it costs in India compared to the United States, and how to organize your care.

What Is PRRT and How Does It Work?

Lutetium Lu-177 dotatate (sold internationally as Lutathera) is a radioligand therapy for GEP-NETs that carry somatostatin receptors on their surface. A somatostatin receptor is a protein on the outside of many neuroendocrine tumor cells. Most GEP-NETs - including pancreatic and midgut NETs - have high levels of these receptors.

The treatment works by attaching a radioactive atom (lutetium-177) to a peptide called dotatate. This peptide naturally finds somatostatin receptors. When it binds to a NET cell, the radiation delivers a dose to the tumor. Healthy tissue nearby gets much less exposure than with conventional external radiation.

Lutathera received approval from the US Food and Drug Administration in January 2018 for adults with somatostatin receptor-positive GEP-NETs. The approval came from the phase 3 NETTER-1 trial. In that trial, patients who got PRRT had longer progression-free survival than those on high-dose octreotide. The hazard ratio was 0.21 in favor of PRRT - tumor progression was much less likely in the treatment group. About 18% of patients receiving PRRT had an objective tumor response, according to published analysis of the NETTER-1 study data.

A standard course of PRRT uses four cycles given as an intravenous infusion, spaced eight weeks apart. The full course takes about six to eight months.

Why Is PRRT Not Yet Available in Nigeria, Kenya, or Ethiopia?

PRRT requires specific facilities and expertise that most hospitals in sub-Saharan Africa don't have yet. These include:

  • A licensed radiopharmacy that can prepare lutetium-177 labeled doses safely
  • Shielded nuclear medicine treatment rooms with proper radiation safety systems
  • Staff trained in radionuclide therapy delivery and monitoring
  • National regulatory approval for radioactive isotopes in clinical care

These are significant gaps. Even in countries with strong healthcare systems, only a limited number of specialist centers offer PRRT. In Nigeria, Kenya, and Ethiopia, nuclear medicine departments focus mainly on diagnostic imaging rather than treatment. This reflects a global infrastructure divide, not a problem with the quality of cancer care in these countries. Much of the developing world faces the same access gap, which is why patients from these regions seek treatment in India, Turkey, and similar destinations with established PRRT programs.

India built this infrastructure earlier than most countries at its development stage. It produces lutetium-177 domestically and has accredited nuclear medicine centers at major hospitals in several cities. Hundreds of international NET patients get PRRT at Indian centers each year.

How Does the Cost of PRRT Compare - India vs the United States?

Estimated PRRT (lutetium Lu-177 dotatate) cost and access by country for GEP-NET patients - 2025
FactorPRRT in IndiaPRRT in the USANigeria / Kenya / Ethiopia
Currently availableYes - multiple accredited centresYes - limited specialist PRRT centresNot currently available
Full 4-cycle course (USD, 2025 est.)USD 4,000-9,000 (varies by hospital and patient profile)Substantially higher - request an itemised quote directly from the centreNot applicable
Medical visa for treatmentTypically processed within days to two weeksVisa requirements vary; can take weeks to months for non-US residentsNot applicable
Eligibility PET scan on-siteGa-68 DOTATATE PET-CT available at most PRRT centresAvailable but access varies by state and centreNot widely available
Typical wait to start treatmentOne to three weeks after eligibility is confirmedWeeks to months, depending on the centre and insurance authorisationNot applicable

India cost estimate sourced from Medserg PRRT cost data (2025). US costs for lutetium Lu-177 dotatate (Lutathera) vary by insurance, hospital, and services included. Always get a detailed written quote from any center before committing to travel.

The cost difference between India and the United States is large. In the US, Lutathera is FDA-approved and available at certified nuclear medicine sites. But the full treatment package - the drug, amino acid infusions for kidney protection, hospital fees, and cycle monitoring - costs far too much for most international patients paying out of pocket. Patients from Nigeria, Kenya, and Ethiopia who pay privately find that India offers a much more affordable option. For a detailed breakdown of what Indian PRRT packages typically include, see Lutathera PRRT cost in India for GEP-NET patients.

What Does PRRT Eligibility Require?

Not every GEP-NET patient is a candidate for PRRT. Confirming eligibility before you travel is essential. Three things matter most.

Somatostatin receptor expression. Your tumor must show uptake on a Ga-68 DOTATATE PET-CT scan. This scan checks whether your tumor cells have enough somatostatin receptors for the dotatate to bind to them. Strong uptake means PRRT is likely to reach your tumor cells. Weak or no uptake means PRRT may not work for you.

Kidney and bone marrow function. Your kidneys must work well because lutetium-177 leaves your body through your kidneys. Doctors check your blood counts, especially red cells and platelets, before each cycle. PRRT can lower your blood counts over the full treatment course.

Tumor grade. PRRT works best on well-differentiated NETs with a Ki-67 index below 20% (grade 1 or 2 by WHO classification). High-grade or poorly differentiated neuroendocrine carcinomas may not respond as well. Your biopsy report, which states the Ki-67 percentage and tumor type, is one of the first documents a specialist will want to see.

If you don't yet have a Ga-68 DOTATATE PET-CT, this scan can be done in India on your first visit - often the same trip as your initial consultation. You won't need to make two separate trips before starting treatment.

The Patient Journey: From Africa to India

Getting from a diagnosis in West or East Africa to receiving PRRT in India involves several steps. Here is what the process typically looks like.

Gather your records. Collect your Ga-68 DOTATATE PET-CT report (if you have one), your biopsy or pathology report with Ki-67 grade, recent blood test results covering blood count, kidney function, and liver function, and records of any prior treatment.

Remote eligibility review. Most accredited Indian PRRT centers will review your documents before you commit to travel. A nuclear medicine specialist reviews your scans and either confirms you are a likely candidate or explains why PRRT may not be suitable and what alternatives may exist. You can send your scans to the Art of Healing Cancer team for review before you book a flight. That way, you know your eligibility status before spending money on travel.

Medical visa. Once eligibility is confirmed and a hospital appointment is scheduled, your Indian hospital issues an appointment letter. This letter is typically needed for a medical visa application. Indian medical visas for cancer treatment usually get processed within days to two weeks. An accompanying family member or caregiver can apply for a medical attendant visa at the same time.

Cycle 1 in India. Your first visit includes a pre-treatment workup - blood tests, kidney function review, and the eligibility Ga-68 DOTATATE PET-CT if not already done - followed by the PRRT infusion itself. The infusion is usually a day procedure.

Return home between cycles. After cycle 1, most international patients return home for the eight-week interval before cycle 2. Your Indian team advises which blood tests to do at a local lab between cycles and reviews those results remotely before you travel back. You don't stay away from your family for the entire treatment period.

For a full breakdown of flights, accommodation, and daily costs in India, see real travel costs for international NET patients.

What to Expect During Your Cycles in India

Each PRRT infusion goes through an IV line and takes about 30 minutes. You also receive an amino acid infusion that runs for several hours to protect your kidneys from radiation exposure. Most patients stay at the hospital for a few hours after the infusion and then go home the same day. Some centers require an overnight stay for radiation safety observation, depending on local protocols.

Common side effects include mild nausea during or just after the infusion and fatigue in the following days. Some lowering of blood counts may occur with repeated cycles. Your care team watches for these effects at each visit. Your team will give you radiation safety guidance to follow for a few days after each cycle - this typically means keeping distance from young children and pregnant women, and following basic hygiene steps.

Between cycles, many patients focus on maintaining their energy and supporting their immune system while blood counts recover. If you want over-the-counter support during this period, you can see the Immunity and Wellness options at Ayurnomics. Always check with your nuclear medicine team before taking any new supplement, since some ingredients may need to be avoided around treatment dates.

How to Start Arranging Your Treatment

If you have a GEP-NET diagnosis, a pathology report with Ki-67 grading, and a Ga-68 DOTATATE PET-CT report, you have the core documents needed to begin an eligibility review. Send these through the Lutetium Therapy contact form to request a review. If PRRT isn't right for your case, the team can suggest other options to discuss with your oncologist.

When to Talk to Your Doctor

Talk to your oncologist or gastroenterologist before making any travel plans for PRRT. Share this article with them and ask for help gathering the records listed above. If you are already receiving a somatostatin analogue - such as octreotide or lanreotide - your care team needs to know. The timing of those injections relative to PRRT cycles matters. Also discuss what follow-up care will look like when you return home between cycles and after the full course is complete.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Is PRRT (Lu-177 DOTATATE) available in Nigeria, Kenya, or Ethiopia?

Not at established hospitals as of 2025. The infrastructure needed to deliver PRRT - including a licensed radiopharmacy, shielded nuclear medicine treatment rooms, and trained specialist staff - is not yet in place in these countries. Patients from this region typically travel to India to access PRRT, which is available at accredited nuclear medicine centres there.

How much does a full course of PRRT cost in India?

Cost estimates from Indian hospital sources suggest that a full 4-cycle course of PRRT may range from approximately USD 4,000 to 9,000, depending on the hospital, the patient's clinical profile, and what the package includes. These figures vary between centres, so always request an itemised written quote from any hospital you are considering before committing to travel.

Do I need to stay in India for all four PRRT cycles?

No. Most international patients return home after each cycle and travel back to India for the next one. The eight-week interval between cycles allows time to return home, complete follow-up blood tests at a local lab, and rest before the next infusion. Your Indian care team reviews your blood results remotely and advises whether you are ready to travel for the next cycle.

What scan do I need to confirm PRRT eligibility?

You need a Ga-68 DOTATATE PET-CT scan. This scan checks whether your tumor cells carry somatostatin receptors at a level high enough for the dotatate molecule to bind to them effectively. If you have not had this scan in your home country, it can be arranged in India on your first visit - often combined with your initial consultation on the same trip.

Can I get a remote second opinion on my PRRT eligibility before travelling?

Yes, and it is strongly recommended. Most reputable PRRT centres in India will review your existing scan reports and pathology results remotely before you book a flight. This remote review helps confirm whether PRRT is likely to be appropriate for your case, and gives you a realistic picture of what treatment will involve and what it is likely to cost.

What documents do I need to bring to India for PRRT?

Bring your Ga-68 DOTATATE PET-CT report, your biopsy or pathology report (including the Ki-67 proliferation index and tumor type), recent blood test results covering full blood count, kidney function, and liver function, records of any prior treatment, and the appointment letter from your Indian hospital. Your care coordinator will provide a full checklist when your visit is confirmed.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

PRRT Cost India | GEP-NET Patients Nigeria Kenya | lutetium-therapy